Psychiatric Times World CME Conference

Here's why more research is important to help us better understand the effects of cannabis on our patients.

How can we, as clinicians, understand how trauma has affected our patients and respond in the most effective way?

Is it prolonged grief or MDD? Expert shares insights at premiere annual meeting.

The president of the San Diego Psychiatric Society gives us a glimpse into the city for the upcoming 2022 Annual Psychiatric Times World CME Conference.

What are their clinical differences?

Which treatment approaches are the state-of-the-art for helping this patient population?

How do you choose medications based on the biologic abnormalities that are known to occur in bipolar illness?

These 3 essential steps best support patients with borderline personality disorder, according to Carl Fleisher, MD.

Cultural differences between patients and physician are hard to avoid. How can you best work with diverse patients?

Transgender youth are at increased risk for a number of psychiatric morbidities. Gender identity conversion therapy can make them worse.

Sheldon Preskorn, MD, shares insights into drug mechanisms and delivery to better help patients with major depressive disorder.

Phase 3 results on MDMA-assisted therapy look promising for the treatment of PTSD. What other disorders can psychedelics help treat?

Sidney Zisook, MD, shares insights into defining depression diagnosis.

Chronic adolescent exposure to THC and cannabis could lead to adverse mental health outcomes and impacted brain functioning.

Health care workers have always been prone to stress and burnout, and the COVID-19 pandemic exacerbated the issue. What do we know about burnout and how can we prevent and address it?

Bringing science to the practice of psychiatry has been the personal goal of Sheldon H. Preskorn, MD—the Educator of the Year.

The pandemic caused the shut down of schools and resulted in virtual learning for most of the world's children and adolescents. How did they fare?

Psychiatric Times' Editor in Chief shared some insights and data on the psychiatric impacts of COVID-19, and what we might expect in the future.

Recognizing the need to stay up-to-date with psychopharmacology and issues affecting psychiatric practice, Psychiatric Times' Editor in Chief invites readers to join him and leaders in psychiatry for a fascinating educational conference.